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Objectives: To determine the expressions of Toll-like receptors (TLRs) 7–9 and type I interferon 
(IFN) signal in labial salivary glands (LSGs) and cultured salivary gland epithelial cells (SGECs) 
from primary Sjögren's syndrome (pSS) patients. 
Methods: We performed an immunohistochemistry analysis of LSGs from 11 patients with pSS as 
defined by American-European Consensus Group classification criteria and five healthy subjects. 
The pSS patients' SGECs were analyzed by immunofluorescence and western blotting. IFN-α 
expression was examined by immunosorbent assay and flow cytometry. 
Results: Mononuclear cells (MNCs) from pSS patients' LSGs showed TLR7-dominant expression. 
B cells, plasma cells, and plasmacytoid dendritic cells (pDCs) co-expressed with TLR7. MyD88, 
TRAF6, and IRF7 co-expressed with the pDC marker CD303 in LSGs. Ducts from pSS patients 
dominantly expressed TLR7, and TLR7 in the ducts co-expressed with MyD88, TRAF6 and IRF7. 
Type I IFNs including IFN-α and IFN-β were detected in MNCs and ducts in pSS patients' LSGs. 
Increased TRAF6 expression and the nuclear translocation of IRF7 in SGECs were detected by 
immunofluorescence following loxoribine (a TLR7 ligand) stimulation despite IFN-β pretreatment. 
Western blotting showed increased TRAF6 expression in SGECs following IFN-β and loxoribine 
stimulation. Although no increase in IFN-α was detected in supernatant from stimulated SGECs, 




Conclusion: Our findings suggest that TLR7 is dominantly expressed in both MNCs and ducts 
with downstream signals for type I IFNs, indicating that TLR7-dominant innate immunity is related 








Primary Sjögren's syndrome (pSS) is a systemic autoimmune disease characterized by periductal 
lymphocytic infiltration of the salivary and lacrimal glands, which results in reduced secretory 
functions and oral and ocular dryness [1]. Although the pathogenesis of pSS is not yet established, 
innate immune responses including type I interferon (IFN) activity were shown to be associated 
with the pathogenesis of pSS [2, 3], as were the conventional acquired immunity responses 
including major histocompatibility class II-mediated antigen presentation [4]. Toll-like receptors 
(TLRs), especially TLRs 7–9, are important innate immune receptors that recognize a range of 
RNA and DNA molecules from viruses and self-antigens, and lead to the production of type I IFN 
via downstream molecules such as myeloid differentiation primary response gene 88 (MyD88), 
tumor necrosis factor receptor-associated factor 6 (TRAF6), and interferon regulatory factor 7 
(IRF7) signaling [5]. The expressions of TLR7 and TLR9 were high in the peripheral blood 
mononuclear cells (PBMCs) of pSS patients [6]. However, little is known regarding the expression 
pattern and the roles of TLR7–9 in the salivary glands. In this study, we analyzed the expressions of 
TLR7–9 in labial salivary glands (LSGs) of pSS patients. Based on the TLR7 dominant expression 
observed, we also analyzed TLR7 downstream signals and function in an in vitro examination. 
 




For the immunohistochemical analysis, we retrospectively analyzed materials from 11 patients with 
pSS and five control subjects who visited Nagasaki University Hospital during the period from 
2008 to 2013. The patients' pSS classification was based on the 2002 American-European 
Consensus Group (AECG) Sjögren's Syndrome (SS) classification criteria [7]. The control subjects 
had sicca symptoms but did not fulfill the AECG SS classification criteria (non-SS sicca control 
subjects). LSG biopsies specimens were obtained from all participants for our assessment of the 
pathological findings of pSS. 
For the determination of focus scores (i.e., the number of foci per 4 mm2) in LSGs, the 
number of foci in a section from LSGs was counted and the surface area of the section was 
measured by a hybrid cell count system mounted on a microscope (BZ-X700; Keyence, Osaka, 
Japan) [8]. The clinical and serological characteristics of the pSS patients and control subjects are 
summarized in Table 1. All patients gave their informed consent to be subjected to the protocol, 
which was approved by the Institutional Ethics Committee of Nagasaki University Hospital 
(approval no. 09102822-3). 
 
Culture of salivary gland epithelial cells (SGECs) 
We performed the culturing of SGECs as described [9]. Briefly, the LSG tissues were cut with fine 
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needles and scalpels and placed in six-well plates coated with type-I collagen (Iwaki, Tokyo) with 
culture medium consisting of defined keratinocyte-SFM culture medium (Invitrogen Life 
Technologies, Carlsbad, CA), 0.4 μg/ml hydrocortisone (Sigma-Aldrich, St. Louis, MO), 25 μg/ml 
bovine pituitary extract (Kurabo, Osaka, Japan), 100 U/ml penicillin, and 100 μg/ml streptomycin 
(Gibco, Grand Island, NY). When an outgrowth of SGECs was observed, the cells were transferred 
into 100-mm2 plates coated with type-I collagen (Iwaki) after the cells reached confluence. After 
the SGECs reached confluence on the 100-mm2 plates, the cells were cultured onto 60-mm2 plates 
coated with type-I collagen (Iwaki) for western blotting and an enzyme-linked immunosorbent 
assay (ELISA). 
When the SGECs reached confluence, the cells were treated with 1 mM loxoribine 
(InvivoGen; San Diego, CA), a TLR7 ligand, for 10 min, 60 min, or 6 hr, and/or 1000 U/ml IFN-β 
(Betaferon®; Bayer Pharma, Berlin, Germany) for 12 hr. For immunofluorescence, SGECs were 
distributed onto 12-mm2 cover slips coated with a Type I collagen, Cellmatrix (Nitta Gelatin, Osaka, 
Japan) in 24-well plates (Corning, New York, NY) after the SGECs reached confluence on the 
100-mm2 plates. Subsequently, the SGECs were treated with 1 mM loxoribine for various lengths 
of time between 0 min and 60 min and/or 1000 U/ml IFN-β for 12 hr. 
 
Isolation and culture of peripheral blood mononuclear cells (PBMCs) 
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Heparinized whole blood (7 ml) was obtained from each pSS patient and control subjects (patients 
other than those described in Table 1). PBMCs were isolated from whole blood by centrifugation 
using Ficoll-Paque™ Plus (GE Healthcare Bio-Sciences, Uppsala, Sweden); the cells were 
subsequently seeded on six-well plates (Iwaki) and cultured in RPMI 1640 medium (Wako, Osaka, 
Japan) supplemented with 10% heat-inactivated fetal bovine serum (Gibco, Paisley, Scotland), 0.25 
μg/ml amphotericin B (Sigma-Aldrich), 100 U/ml penicillin, and 100 μg/ml streptomycin (Gibco). 
The cells were then treated with 1 mM loxoribine for 6 hr and/or 1000 U/ml IFN-β for 12 hr for the 
ELISA and flow cytometry. 
 
Immunohistochemistry (IHC) 
We performed IHC to examine the expressions of TLR7–9 and TLR7 downstream molecules in 
LSGs. A cancer tissue array including four types of cancer — colon, breast, lung, and 
prostate — and normal tissue (US Biomax, Derwood, MD) was used as the positive control for 
TLR7–9 expression. The primary antibodies used were rabbit anti-TLR7 polyclonal (working 
dilution 1:100; Enzo Life Sciences, Farmingdale, NY), rabbit anti-TLR8 polyclonal (working 
dilution 1:100, Sigma-Aldrich), rabbit anti-TLR9 polyclonal (working dilution 1:100; Bioss 
Antibodies, Woburn, MA), mouse anti-IFN-α monoclonal (working dilution 1:100, Santa Cruz), 
and rabbit anti-IFN-β polyclonal antibody (working dilution 1:100, Abcam, Cambridge, MA). 
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In summary, paraffin-embedded sections from LSGs and the tissue array were incubated 
with 3% H2O2 solution for the inhibition of endogenous peroxidase activity after microwave 
epitope retrieval, and blocked with 5% normal horse serum. They were incubated with each 
primary antibody diluted with 5% normal horse serum for 60 min at room temperature (RT), 
followed by peroxidase-conjugated secondary antibody (Histofine Simple Stain, Nichirei 
Biosciences, Tokyo) for 30 min at RT. After incubation, they were reacted with 
3, 3'-diaminobenzidine solution for 10 min and counterstained with hematoxylin solution. Images 
were taken using a digital microscope color camera (DFC295; Leica Microsystems, Tokyo). 
 
Immunofluorescence 
We performed an immunofluorescence examination to determine the localization of TLR7, TLR8, 
and TLR7 downstream molecules in mononuclear cells (MNCs) of LSGs in vivo, and the 
expression of TLR7 downstream molecules in SGECs in vitro. The primary antibodies used were 
rabbit anti-TLR7 polyclonal (working dilution 1:100), mouse anti-TLR7 monoclonal (working 
dilution 1:100; Thermo Fisher Scientific, Rockford, IL), rabbit anti-TLR8 polyclonal (working 
dilution 1:100), rabbit anti-MyD88 polyclonal (working dilution 1:100, Santa Cruz), rabbit 
anti-TRAF6 monoclonal (working dilution 1:100; Abcam), rabbit anti-IRF7 polyclonal (working 
dilution 1:100; Abnova, Taipei City, Taiwan), mouse anti-CD4 monoclonal (working dilution 
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1:100; Agilent Technologies, Santa Clara, CA), mouse anti-CD8 monoclonal (working dilution 
1:100, Agilent Technologies), mouse anti-CD20 monoclonal (working dilution 1:1, Agilent 
Technologies), mouse anti-CD68 monoclonal (working dilution 1:100, Agilent Technologies), 
mouse anti-VS38c monoclonal (working dilution 1:100, Agilent Technologies), and mouse 
anti-CD303 antibody (working dilution 1:100; Dendritics, Lyon, France) in vivo, and rabbit 
anti-TRAF6 monoclonal antibody (working dilution 1:100) and rabbit anti-IRF7 polyclonal 
antibody (working dilution 1:100) in vitro. The procedure until incubation with primary antibodies 
was basically the same as that of the IHC in vivo. 
After incubation with primary antibodies, the sections from LSGs were reacted with 
secondary antibodies including donkey anti-mouse IgG conjugated with fluorescein isothiocyanate 
(FITC) antibody (Jackson ImmunoResearch Laboratories, West Grove, PA), donkey anti-rabbit IgG 
conjugated with tetramethyl rhodamine isothiocyanate (TRITC) antibody (Jackson 
ImmunoResearch), and Hoechst dye 33258 (Sigma-Aldrich) for 45 min at RT in the dark. The 
sections were then mounted in Vectashield mounting medium (Vector Laboratories, Burlingame, 
CA). 
In vitro, SGECs on 12-mm2 cover slips were incubated in 4% paraformaldehyde for 10 min 
at 4°C and then immersed in methanol for 10 min at −20°C after loxoribine and/or IFN-β 
stimulation. The cells were blocked with 5% normal horse serum and incubated in each primary 
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antibody for 60 min at RT, followed by secondary antibodies including rabbit anti-IgG conjugated 
with TRITC and Hoechst dye 33258 for 45 min at RT in the dark. The cells were subsequently 
mounted in Vectashield mounting medium. Images were captured by a microscope (BZ-X700). The 
mean fluorescence intensity (MFI) of cells in a given area was calculated by the hybrid cell count 
system that was mounted on the BZ-X700 microscope. 
 
Terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL) staining 
We performed TUNEL staining to examine apoptosis in SGECs, as described [10]. Briefly, we used 
a Mebstain Apoptosis Kit Direct (MBL, Nagoya, Japan). After the SGECs were treated with 
loxoribine for 6 hr and/or IFN-β for 12 hr, or 50 ng/ml recombinant tumor necrosis factor-related 
apoptosis inducing ligand (TRAIL) (R&D Systems Minneapolis, MN) for 3 hr as a positive control, 
the cells were incubated with 50 μl of terminal deoxynucleotidyl transeferase (TdT) solution at 
37°C for 1 hr after incubation with TdT buffer for 10 min. The cells were subsequently mounted in 
Vectashield mounting medium. Images were captured by a microscope (BZ-X700). 
 
Western blotting 
We performed western blotting to detect the protein of TLR7, its downstream molecules, and other 
molecules (B-cell activating factor [BAFF], Ro52, and major histocompatibility [MHC] class I) 
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after stimulation with loxoribine and/or IFN-β. Western blotting was performed as described [9]. 
After SGECs were lysed and the protein concentrations were measured, identical amounts of 
protein were subjected to 12.5% sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE). The proteins were transferred to a polyvinylidene fluoride (PVDF) filter, and the 
filter was blocked using 5% nonfat dried milk in Tris-buffered saline containing 0.1% Tween 20 
(TBS-T) for 60 min, and incubated with rabbit anti-TLR7 polyclonal antibody (working dilution 
1:250), rabbit anti-TRAF6 monoclonal antibody (working dilution 1:1000), mouse anti-BAFF 
monoclonal antibody (working dilution 1:1000; Novus Biologicals, Littleton, CO), rabbit 
anti-MHC class I polyclonal antibody (working dilution 1:1000; Proteintech, Rosemont, IL) or 
rabbit anti-Ro52 polyclonal antibody (working dilution 1:1000; Cloud-Clone Corp; Katy, TX) at 
4°C overnight, or mouse anti-β actin monoclonal antibody (working dilution 1:5000, Santa Cruz) 
for 60 min at RT. 
The filter was then washed with TBS-T and incubated with mouse or rabbit anti-IgG coupled 
with horseradish peroxidase (HRP) as secondary antibodies (working dilution 1:1000; MBL). After 
the incubation, we used an Amersham Hyperfilm enhanced chemiluminescence system (GE 
Healthcare UK, Little Chalfont, UK) for the detection of the bands. The density of each band was 
measured by Image J software developed at the U.S. National Institutes of Health for the 





The levels of IFN-α in the culture supernatants of SGECs and PBMCs after stimulation with 
loxoribine and/or IFN-β were measured using the VeriKine™ Human IFN-α ELISA Kit (Product 
#41100, PBL Assay Science, Piscataway, NJ) following the manufacturer's instructions. Briefly, the 
cells were seeded on 96-well ELISA plates and incubated for 60 min at RT. They were incubated 
with detection antibody for 60 min at RT, followed by HRP-conjugated secondary antibody for 60 
min at RT. After that, they were incubated with substrate solution for 15 min at RT, and stop 




After the isolated PBMCs from three pSS patients were stimulated with loxoribine and/or IFN-β 
followed by treatment with 5 μg/ml of brefeldin A for 12 hr to save the IFN-α activity, the PBMCs 
were stained with phycoerythrin (PE)/Cy7-conjugated mouse anti-CD123 antibody (Biolegend, San 
Diego, CA) and allophycocyanin (APC)-conjugated mouse anti-CD303 antibody (Biolegend) for 
30 min at 4°C. After permeabilization, the PBMCs were stained with FITC-conjugated mouse 
anti-IFN-α antibody (MACS Miltenyi Biotek, Bergisch Gladbach, Germany) and PE-conjugated 
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mouse anti-TLR7 antibody (ThermoFisher Scientific) at 4°C overnight, and they were then 
analyzed by flow cytometry using a BD FACS Verse (BD Biosciences, San Jose, CA) and FlowJo 
ver. 10 software (Tree Star, Ashland, OR). PE/Cy7-conjugated mouse IgG1, APC-conjugated 
mouse IgG1, FITC-conjugated mouse IgG2a, and PE-conjugated mouse IgG1 (Biolegend) were 
used as isotype controls. 
 
Statistical analysis 
We used the Mann-Whitney U-test or Fisher's exact test to compare the clinical and serological 
characteristics between the pSS and control groups, and a repeated-measures analysis of variance 
(ANOVA) to determine the differences in protein expressions detected by western blotting and the 
percentages of IFN-α+ cells measured by flow cytometry. Spearman's rank correlation coefficient 
was used to determine the correlation between the mean fluorescence intensity of IFN-α or TLR7 
stains in the mononuclear cells of LSGs and the percentage of IFN-α+TLR7+ cells among the 
PBMCs. 
All statistical analyses in this study were performed using JMP software, ver. 13 (SAS, Cary, 






Table 1 summarizes the characteristics of the 11 patients and the five control subjects. All of the 
pSS patients were female. The group of pSS patients had significantly greater anti-SS-A/Ro 
antibody and anti-nuclear antibody positivity, and significantly higher serum IgG levels and LSG 
biopsy focus scores compared to the control group (p<0.001, p<0.001, p=0.009 and p=0.0019). 
 
The dominant expression of TLR7 in the MNCs and ducts of the pSS patients' LSGs 
The expression levels of TLR7 were stronger in infiltrating MNCs and ducts of LSGs from the pSS 
patients compared to those of the control subjects (Fig. 1A,D). In contrast, TLR9 was weakly 
expressed in the MNCs and ducts from both the pSS patients and controls (Fig. 1C,F). TLR8 was 
expressed in the MNCs of several pSS patients (Fig. 1B,E). The immunostaining results for TLR7–
9 are summarized in Supplementary Table S1. 
 
The dominant expression of TLR7 in plasmacytoid dendritic cells (pDCs), CD8+ T cells, B cells, 
and plasma cells of LSGs from the pSS patients 
To clarify which cells expressed TLR7, we performed double immunofluorescence staining with 
TLR7 and several cell markers in LSGs from the pSS patients. The results showed that the 
TLR7-positive cells were co-localized mainly with plasmacytoid dendritic cells (pDCs; 
CD303-positive cells). CD8+ T cells (CD8-positive cells), B cells (CD20-positive cells), and 
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plasma cells (VS38c-positive cells) were also co-localized with TLR7-positive cells, next to the 
co-localization of pDCs, whereas other cell marker-positive cells were partly co-localized with 
TLR7-positive cells (Fig. 2). We also performed double immunofluorescence staining with TLR8 
and several cell markers in LSGs from the pSS patients, and the results demonstrated that 
TLR8-positive cells were also co-localized mainly with pDCs (CD303-positive cells) (Suppl. Fig. 
S1). 
 
The expression of TLR7 downstream molecules in pDCs from the pSS patients 
We examined the results of the double immunofluorescence staining for TLR7 downstream 
molecules and CD303 in LSGs from the pSS patients, and we observed that TLR7 was expressed in 
pDCs. TLR7 downstream molecule (MyD88, TRAF6 and IRF7)-positive cells as well as 
TLR7-positive cells were co-localized mainly with pDCs (Fig. 3). 
 
The expression of TLR7 and its downstream molecules in ducts from the pSS patients 
We examined the results of the IHC staining with TLR7 downstream molecules in ducts of LSGs 
from the pSS patients. TLR7 was strongly expressed in ducts of LSGs from the pSS patients 
compared to the expressions of TLR8 and TLR9 (Fig. 4A). In the serial sections, 
immunofluorescence showed that the TLR7 downstream molecules MyD88, TRAF6, and IRF7 
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were also expressed in ducts of LSGs from the pSS patients (Fig. 4B). In addition, the expression 
levels of type I IFNs (IFN-α and IFN-β) were also stronger in the MNCs and ducts of LSGs from 
the pSS patients compared to those of the control subjects (Fig. 5A). 
 
Activation of TLR7 signaling stimulated by TLR7 ligand in SGECs and PBMCs 
We examined the expression of TLR7 signaling in SGECs after stimulation with TLR7 ligand, and 
we observed that TLR7 signaling was expressed in LSG ducts from the pSS patients. Our 
time-course experiments using immunofluorescence staining showed that TRAF6 expression was 
most strongly detected, and IRF7 expression was most aggregated around the nuclei, suggesting 
that IRF7 was translocated into the nucleus after stimulation with loxoribine for 10 min as well as 
by loxoribine for 10 min and IFN-β for 12 hr (Fig. 5B). In the western blotting, the expressions of 
TLR7 and TRAF6 were not changed by stimulation with loxoribine for 10–60 min and/or IFN-β 
(data not shown). However, the TRAF6 expression was significantly increased by stimulation with 
IFN-β coupled with loxoribine for 6 hr. In contrast, the TLR7 expression was not changed by 
stimulation with IFN-β and/or loxoribine for 6 hr (Fig. 5C). IFN-α was not detected in the 
supernatants of SGECs in the presence of IFN-β and/or loxoribine by ELISA. 
In contrast, the ELISAs showed that the levels of IFN-α were increased after stimulation 
with loxoribine and IFN-β in the supernatants of PBMCs from the pSS patients (Fig. 6A). 
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Additionally, the flow cytometry revealed a significant increase in IFN-α after stimulation with 
loxoribine and IFN-β in TLR7+CD123/303+ pDCs from the pSS patients (Fig. 6B). ELISAs also 
showed a significant increase in IFN-α in supernatants from the control subjects following 
stimulation with loxoribine and IFN-β (data not shown). 
We also examined the correlation between the MFI of IFN-α or TLR7 stains in mononuclear 
cells of LSGs revealed by immunofluorescence and the percentage of IFN-α+TLR7+ plasmacytoid 
dendritic cells among PBMCs after stimulation with loxoribine and IFN-β shown by flow 
cytometry from the same pSS patients. The results showed a tendency toward a positive correlation 
between IFN-α or TLR7+ mononuclear cells of LSGs and IFN-α+TLR7+ plasmacytoid dendritic 
cells among PBMCs (Fig. 6C). 
 
Apoptosis and activation of BAFF, Ro52, and MHC class I stimulated by TLR7 ligand in SGECs 
We examined the induction of apoptosis and the activation of BAFF, Ro52, and MHC class I in 
SGECs after stimulation with a TLR7 ligand. TUNEL staining showed that apoptosis was not 
induced by stimulation with loxoribine and/or IFN-β (Suppl. Fig. S2A). Although neither apoptosis 
nor BAFF expression was induced by loxoribine and/or INF-β, both Ro52 and MHC class I were 





The findings revealed by our present analyses indicate that TLR7 and its downstream signaling are 
expressed strongly in ducts and MNCs (especially pDCs) of labial salivary glands from pSS 
patients in vivo, and we observed that TLR7 downstream molecules are expressed in SGECs from 
pSS patients after TLR7 ligand stimulation in vitro. A key contributor to the development of pSS is 
thought to be an adaptive immune response in which self-reactive T cells recognize autoantigens 
such as M3 muscarinic acetylcholine receptor (M3R) [11] and alpha-fodrin [12]. The involvement 
of innate immune activity was recently reported to be related to the pathogenesis of many 
autoimmune diseases [13]. TLR7–9 are representative pattern recognition receptors that recognize 
the nucleic acid sequences of viruses and self-antigens, and these activities produce cytokines such 
as type I IFN or induce the activation of the nuclear factor kappa B (NFκB) pathway [5]. 
Previous studies identified the overexpression of type I IFN-inducible genes such as 
IFN-α-inducible protein 27 (IFI27), IFN-induced transmembrane protein 3 (IFITM3), 
IFN-stimulated transcription factor 3 (ISGF3G), and IRF1 in the salivary glands and peripheral 
blood from pSS patients, suggesting that the type I IFN pathway is a key player in the pathogenesis 
of pSS [2, 3, 14]. Our earlier investigation demonstrated the expression and function of TLR2–4 in 
patients with SS [15], and in the present study we focused on TLR7–9 from the view point of 
receptors of nucleic acid sequences of viruses and/or self-antigens. 
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Several studies showed that TLR7–9 are expressed in PBMCs from SS patients [6, 16, 17] 
and one study suggested that apoptosis induced TLR7 and -9 expressions in pDCs [18]. However, 
the expression of TLR7–9 in salivary glands has not been well investigated. Zheng et al. reported 
that TLR7 and TLR9 were dominantly expressed in lymphocytes of the parotid glands from pSS 
patients compared to those of control subjects [6]. In contrast, Maria et al. reported that TLR7 was 
expressed by few cells within the lymphocytic foci [16]. Our present findings demonstrate that 
TLR7 was more strongly expressed than TLR9 in mononuclear cells of labial salivary glands. 
Because the expression of TLR7–9 was confirmed by positive control sections, the dominant 
expression of TLR7 in mononuclear cells was evident in our severely infiltrated samples from the 
pSS patients. 
Fukui et al. reported that the multitransmembrane endoplasmic reticulum (ER)-resident 
protein Unc93B1 dominantly up-regulated TLR7 ligand-induced activity due to a down-regulation 
of TLR9 ligand-induced activity [19]. It was reported that single-strand RNA (ssRNA) as a TLR7 
ligand was recognized by TLR7 but not TLR8 and activated the transcription of TNFα in synovial 
tissues from rheumatoid arthritis patients, suggesting that the activation of TLR7 was more closely 
associated with inflammation compared to TLR8 activation [20]. Similarly, TLR7-mediated 
activation might dominantly occur in pDCs of labial salivary glands from pSS patients. Alveolar 
macrophages and dendritic cells produced interleukin (IL)-33 induced by TLR7 activation in the 
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respiratory tract of respiratory syncytial virus ssRNA-infected mice [21]. These findings strongly 
suggest the dominance of TLR7 with respect to the provocation of inflammation in LSGs. 
Our present data demonstrated the strong expression of TLR7 in the ducts of labial salivary 
glands from pSS patients. We also evaluated the downstream signaling of TLR7 expressed in the 
ducts of labial salivary glands and TLR7-mediated signal transduction in our in vitro experiments. 
Our findings suggest that the ducts as well as mononuclear cells are involved in TLR7-mediated 
inflammation. Because TLR7 was expressed mainly in mononuclear cells (including pDCs and B 
cells), we speculate that the TLR7 signaling activation in the ducts is associated with mononuclear 
cells that expressed TLR7. However, the expression of TLR7 signaling in SGECs after stimulation 
with a TLR7 ligand in our in vitro analysis revealed that TLR7 signaling was activated in epithelial 
cells independently. 
Another study showed that TLR7 was expressed in HSY cells (human salivary gland cells), 
whereas the levels of IL-6 and IL-8 in cultured supernatants did not increase after stimulation with 
ssPoly U as a TLR7 ligand [22]. Spanchidou et al. reported that immunoregulatory molecules 
including intercellular adhesion molecule-1, CD40, and MHC class I were up-regulated after 
stimulation with TLR2–4 ligands in SGECs from pSS patients, suggesting that epithelial cells 
affected the role of the innate immune response [23]. Additionally, an analysis of a murine model of 
SS revealed that epithelial cell apoptosis was essential for the development of inflammation [24]. 
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These data support the concept that epithelial cells have an important role in inflammation, 
including the activation of innate immunity. 
Because it was reported that IFN-β pretreatment with loxoribine led to an increased 
production of IFN-α upon loxoribine stimulation in PBMCs from patients with multiple sclerosis 
[25], we analyzed SGECs and PBMCs stimulated with IFN-β in addition to loxoribine. However, 
the level of IFN-α in the cultured supernatant of SGECs was not detected by an ELISA. In contrast, 
the expression of IFN-α in TLR7+CD123/303+ pDCs in cultured PBMCs from our pSS patients 
was significantly increased after stimulation with IFN-β and loxoribine. In light of these findings, 
we suspected that the production of IFN-α might depend on a synergistic action of IFN-β and TLR7 
ligation. Eventually, we confirmed that compared with SGECs, the TLR7-positive pDCs among 
PBMCs had a crucial role with respect to the IFN-α production and secretion mechanism in pSS, 
considering that no IFN-α was secreted by stimulated SGECs regardless of the positive expression 
of IFN-α in the ducts of labial salivary glands. With regard to the secretion of soluble factors from 
SGECs in response to IFNs, there is a report [26] showing that the secretion of BAFF was 
upregulated by stimulation with IFNs such as IFN-γ and IFN-α. That report suggested that SGECs 
might have various functions to secrete some soluble factors in response to IFNs, although IFN-α 
itself was not secreted into the culture medium. 
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As noted above, the increased type I IFN activity observed in the salivary glands and 
peripheral bloods from pSS patients in previous studies. However, the relationship regarding TLR7 
signaling between PBMCs and MNCs in salivary glands from pSS patients remains unclear. Our 
present results demonstrated only a tendency toward a positive correlation between IFN-α+ or 
TLR7+ cells of LSGs and IFN-α+TLR7+ cells of PBMCs that were obtained from the same pSS 
patients, suggesting that the TLR7 signal activation was not always correlated between peripheral 
blood and salivary glands. 
Our present findings demonstrated TLR7 expression in CD8+ T cells in labial salivary 
glands from the pSS patients. In general, TLR7 was weakly expressed in CD8+ T cells. Another 
study indicated that TLR7 signaling enhanced the cross-priming of CD8+ T cells, suggesting that 
this signaling may have influenced the TLR7 expression itself [27]. 
An earlier investigation showed that apoptotic particles induced TLR7 and TLR9 expressions 
in pDCs in vitro [18]. Although our prior study demonstrated that TLR3 signal activation induced 
apoptosis in SGECs from individuals with pSS [9], it is not yet known whether stimulation of the 
TLR7 signaling pathway induces apoptosis. However, our present experiments demonstrated that 
TLR7 signal activation induced no apoptosis regardless of type I IFN activation in SGECs from the 
pSS patients. 
We also investigated the expression of relevant molecules including Ro52 and MHC class I 
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(Suppl. Fig. S2). Since we observed a significant increase of Ro52 with loxoribine stimulation with 
IFN-β, we speculated that a TLR7-mediated augmentation of SS-related antigen exists. Because 
Higgs et al. reported that TLR7 stimulation promoted the association of Ro52 with IRF7 [28], 
TLR7 might have a pathogenic function with regard to the control of the expression of Ro52. In, 
addition, we observed that stimulation with loxoribine and IFN-β augmented MHC class I 
expression in SGECs. Although it has been shown that another TLR7 agonist, i.e., imiquimod, 
weakly up-regulated MHC class I in vaginal epithelial cells [29], our present findings might 
demonstrate a specific effect of TLR7 stimulation on SGECs regarding the association of 
endogenous antigen. 
Several limitations of this study should be mentioned. First, we analyzed the expression of 
TLRs in mainly pDCs among mononuclear cells. In future analyses, we should analyze the 
expression of TLR7 in another cell type such as B cells. Because TLR7 has the potential to induce 
autoantibody production through B-cell activation, a TLR7-mediated autoantibody production 
system in SS should be investigated in future studies. Second, a recent study showed that retinoic 
acid-inducible gene-I (RIG-I) and melanoma differentiation associated gene-5 (MDA5) (as innate 
sensors associated with the production of type I IFNs other than TLRs) were up-regulated in pDCs 
and monocytes and highly expressed in mononuclear cells of LSGs from IFN-positive pSS patients 
[13]. Because it has been reported that the expressions of RIG-I and MDA5 are induced by TLR7 
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signal activation, we should analyze these functions in LSGs in future studies. Because the 
upregulation of cyclic GMP-AMP synthase (cGAS), a stimulator of interferon genes (STING) 
pathway, was shown in monocytes of patients with systemic lupus erythematosus [30], the 
pathogenic characteristics of these molecules in pSS should also be investigated. As a third 
limitation of the present study, we did not perform peripheral blood transcriptomics or gene 
expression analysis for the 11 pSS patients. 
In conclusion, the results of our analyses showed that TLR7 signaling for type I IFNs is 
strongly expressed in ducts and mononuclear cells — especially the plasmacytoid dendritic cells of 
labial salivary glands — from pSS patients. Our findings suggest that TLR7-mediated downstream 
signals might be activated due to stimulation with ssRNA. In addition, ductal epithelial cells as 
non-immune cells as well as mononuclear cells expressed TLR7, indicating that it is possible that 
ductal epithelial cells per se act as receptors of adventive microbes and/or endogenous antigens. To 
investigate these speculations, it is desirable to determine whether or not the direct activation of 
microbes and/or self-antigens with ssRNA activates epithelial cells from patients with pSS. By 
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Table 1. Background information of enrolled subjects 
Variables pSS (n=11) Non-SS (n=5) p-value
Age (yrs), median (IQR) 61 (57–65) 52 (40–68) 0.65a
Female, n (%) 11 (100%) 5 (100%) 1b
Xerostomia, n (%) 10 (90.9%) 3 (60%) 0.21b
Xerophthalmia, n (%) 6 (54.5%) 3 (60%)  1b
Schirmer test positivity, n (%) 4 (36.4%)  2 (40%) 0.84b
Saxon test positivity, n (%) 9 (81.8%) 3 (60%) 0.35b
Anti-SS-A/Ro antibody positivity, n (%) 11 (100%) 0 (0%) <0.001b
Anti-SS-B/La antibody positivity, n (%) 4 (36.3%) 0 (0%) 0.12b
ANA positivity, n (%) 11 (100%) 0 (0%) <0.001b
RF positivity, n (%) 7 (63.6%) 4 (80%) 0.51b
Serum IgG, mg/dl, median (IQR) 2140 (1550–2550) 1047 (656–1246) 0.009a
LSG biopsy, focus score 6.9 (4–19.2) 0  0.0019a 
ESSDAI score, median (IQR) 6 (4–6) n.a. n.a.
Non-SS: These subjects were classified as non-SS sicca control subjects based on the AECG classification 
criteria. aMann-Whitney U-test. bFisher's exact test. P-values <0.05 were considered significant. ANA: 
anti-nuclear antibody, ESSDAI: European League Against Rheumatism Sjögren's Syndrome Disease Activity 
Index, IgG: immunoglobulin G, IQR: interquartile range, LSG: labial salivary gland, n.a.: not assessed, pSS: 










 pSS Non-SS 
No. 1 2 3 4 5 6 7 8 9 10 11 1 2 3 4 5 
TLR7 MNCs ++ ++ ++ ++ ++ ++ ++ ++ ++ ++ NA − ± − ± ± 
Ducts ++ ++ ++ ++ ++ ++ ++ ++ ++ ++ NA ++ ++ − − − 
TLR8 MNCs + ± + − + ± ± ++ ++ + NA − + − − ± 
Ducts − − − − − − − − − − NA − ± − − − 
TLR9 MNCs − − ± − NA − − ± − − − − − − − ± 
Ducts − − ± ± NA + + ± ± ± + − − − ± ± 
The frequency of TLR7–9 positive area: ++ > 50%, +=11–50%, ±=1–10% and −=0% of MNCs in each focus, and 
ducts in each 4 mm2 section. 
Non-SS: These subjects were classified as non-SS sicca control subjects based on the AECG classification criteria. 








Fig. 1. Expressions of Toll-like receptors (TLRs) 7–9 in labial salivary glands (LSGs) from the 
primary Sjögren's syndrome (pSS) patients and non-SS sicca control subjects. Representative 
samples of LSGs stained with anti-TLR7 (A), anti-TLR8 (B), and anti-TLR9 antibodies (C) from 
pSS patients (n=10). Representative samples of LSGs from non-SS patients (n=5) and cancer tissue 
array (right lower panels) stained with anti-TLR7 (D), anti-TLR8 (E), and anti-TLR9 antibody (F). 
Insets: Representative staining in the cancer tissue array. Bar: 80 μm (LSGs), 200 μm (cancer tissue 
array). Non-SS: These subjects were classified as non-SS sicca control subjects based on the AECG 
classification criteria. 
 
Fig. 2. Co-localization of TLR7 and mononuclear cells (MNCs) in LSGs from the pSS patients. 
Representative samples of LSGs stained with cell markers for T cells (anti-CD4 and anti-CD8 
antibodies), B cells (anti-CD20 antibody), plasma cells (anti-VS38c antibody), macrophages 
(anti-CD68 antibody), or pDCs (anti-CD303 antibody) (green), and anti-TLR7 antibody (red) from 
pSS patients (n=3). Hoechst (blue) was used for counterstaining the nuclei. Insets: Representative 




Fig. 3. Expression of TLR7 and its downstream molecules in plasmacytoid dendritic cells 
(pDCs) of LSGs from the pSS patients. Representative samples of LSGs from pSS patients (n=4) 
stained with a cell marker for pDCs (anti-CD303 antibody) (green) and anti-TLR7 (A), 
anti-MyD88 (B), anti-TRAF6 (C), or anti-IRF7 antibody (D) (red). Hoechst (blue) was used for 
counterstaining the nuclei. White arrowheads: The expression of TLR7 or its downstream 
molecules in pDCs. Bar: 20 μm. IRF7: interferon regulatory factor 7, MyD88: myeloid 
differentiation primary response gene 88, TRAF6: tumor necrosis factor receptor associated factor 
6. 
 
Fig. 4. Expression of TLR7 and its downstream molecules in ducts of LSGs from the pSS 
patients. A: Representative samples showing the expressions of TLR7–9 in LSGs from pSS 
patients. Insets: Representative ductal expressions of TLR7–9. Bar: 80 μm. B: Representative 
samples of LSGs from pSS patients (n=5) stained with anti-TLR7 (green), anti-MyD88, 
anti-TRAF6, and anti-IRF7 antibody (red). Hoechst (blue) was used for counterstaining the nuclei. 
White arrowheads: The same ductal expression, using serial sections. Bar: 20 μm.  
 
Fig. 5. Expression of type I IFNs in LSGs and TLR7 signal activation in salivary gland 
epithelial cells (SGECs). A: Representative samples showing the expressions of IFN-α and IFN-β 
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in LSGs from pSS patients (n=4) and non-SS patients (n=4). Bar: 20 μm. Insets: Representative 
expressions of IFN-α and IFN-β. B: Representative images showing the expressions of TRAF6 and 
IRF7 (red) in SGECs from pSS patients (n=3). Bar: 20 μm. C: TLR7 and TRAF6 signal in SGECs 
from pSS patients (n=5) stimulated with 1 mM loxoribine for 6 hr and/or 1000 U/ml IFN-β for 12 
hr analyzed by western blotting. *p<0.05 by ANOVA. Error bars: std. dev. NS: not significant. 
 
Fig. 6. TLR7 signal activation in SGECs and PBMCs from the pSS patients. A: The levels of 
IFN-α in SGECs and PBMCs from pSS patients (n=6) stimulated with 1 mM loxoribine for 6 hr 
and/or 1000 U/ml IFN-β for 12 hr measured by ELISA. B: The expressions of IFN-α and TLR7 in 
CD123+CD303+ pDCs from pSS patients (n=6) stimulated with 1 mM loxoribine for 6 hr and/or 
1000 U/ml IFN-β for 12 hr, analyzed by flow cytometry. **p<0.01 by ANOVA. Error bars: std. dev. 
C: The correlation between the mean fluorescence intensity (MFI) of IFN-α or TLR7 stains in 
mononuclear cells of LSGs and the percentage of IFN-α+TLR7+ pDCs in flow cytometry from pSS 
patients (n=6). The MFI of immunostaining was captured and calculated with a hybrid cell count 
system. The correlations were determined using Spearman's rank correlation coefficient. P-values 
<0.05 were considered significant. ND: not detected, PBMC: peripheral blood mononuclear cell. 
 
Supplementary Fig. S1. Co-localization of TLR8 and MNCs in LSGs from the pSS patients. 
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Representative samples of LSGs stained with cell markers for T cells (anti-CD4 and anti-CD8 
antibodies), B cells (anti-CD20 antibody), plasma cells (anti-VS38c antibody), macrophages 
(anti-CD68 antibody), or pDCs (anti-CD303 antibody) (green), and anti-TLR8 antibody (red) from 
pSS patients (n=2). Hoechst (blue) was used for counterstaining the nuclei. Insets: Representative 
staining for each panel. Bar: 40 μm. 
 
Supplementary Fig. S2. The apoptosis and expressions of BAFF, Ro52, and MHC class I in 
SGECs from the pSS patients. A: Representative images showing the TUNEL staining (green) in 
SGECs from pSS patients (n=3). Bar: 20 μm. Hoechst (blue) was used for counterstaining of the 
nuclei. B: BAFF, C: Ro52, D: MHC class I signal in SGECs from pSS patients (n=5) in which the 
SGECs were stimulated with 1 mM loxoribine for 6 hr and/or 1000 U/ml IFN-β for 12 hr, analyzed 
by western blotting. **p<0.01 by ANOVA. Error bars: std. dev. BAFF: B-cell activating factor, 
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